Mengis Capital Management’s AstraZeneca AZN Stock Holding History

Mengis Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.86M	Buy	46,736 +38	+0.1%	+$7.15K	1.35%	18
2026 Q1	$9.21M	Buy	46,698 +17	+0%	+$3.28K	1.59%	16
2025 Q4	$8.58M	Buy	46,681 +3,260	+8%	+$572K	1.52%	16
2025 Q3	$6.66M	Buy	43,421 +6,991	+19%	+$1.06M	1.31%	18
2025 Q2	$5.09M	Buy	36,430 +6,075	+20%	+$851K	1.08%	21
2025 Q1	$4.46M	Buy	+30,355	New	+$4.39M	0.93%	25

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mengis Capital Management's AZN Position: Q2 2026 in Review

Mengis Capital Management increased its AstraZeneca (AZN) stake by 0.08% in Q2 2026, buying an estimated $7.15K and bringing the position to 46,736 shares worth $8.86M. The position accounts for 1.35% of the portfolio, ranked #18.

Mengis Capital Management first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.21M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Mengis Capital Management held 46,736 shares of AstraZeneca worth $8.86M as of Q2 2026.
Mengis Capital Management bought 38 AstraZeneca shares in Q2 2026, an estimated $7.15K.
AstraZeneca made up 1.35% of Mengis Capital Management's portfolio in Q2 2026, its #18 holding.
Mengis Capital Management first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
Mengis Capital Management's AstraZeneca position peaked at $9.21M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mengis Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.